Mark Taylor, MD, a consultant psychiatrist from The Edinburgh Practice and a professor in the school of medicine and dentistry at Griffith University.

Semaglutide Linked to Lower Suicidality Risk in Diabetes, With Mark Taylor, MD

New data suggest glucagon-like peptide-1 (GLP-1) receptor agonists, particularly semaglutide, are associated with lower risks of anxiety and 

 This contradicts prior concerns raised by the US Food and Drug Administration (FDA) regarding a potential link between GLP-1 therapies and suicidal ideation.

The FDA could not find evidence of this association after an investigation.

“If I were a GP or a diabetologist in the States, I'd be seriously looking at the results [of] this study to inform my choices,” Mark Taylor, MD, a consultant psychiatrist from The Edinburgh Practice and a professor in the school of medicine and dentistry at Griffith University in Australia, told 

“It is quite a powerful result, albeit a correlative or associative result rather than a definitive causality result.”

The Swedish registry-based analysis included 95,490 individuals with depression or anxiety who were prescribed antidiabetic medications between 2009 and 2022.

 Using a within-individual design to minimize confounding, investigators compared periods of GLP-1 receptor agonist use with non-use in the same patients.

Semaglutide was associated with a 42% reduced risk of worsening mental illness (adjusted hazard ratio [aHR], 0.58; 95% CI, 0.51 – 0.65), while liraglutide showed a more modest benefit (aHR, 0.82; 95% CI, 0.76–0.89). No significant associations were observed for exenatide or dulaglutide.

Secondary outcomes further supported semaglutide’s potential psychiatric benefit, including reduced risks of worsening depression (aHR, 0.56), anxiety (aHR, 0.62), and substance use disorder (aHR, 0.53). At the class level, GLP-1 receptor agonists were also associated with a lower risk of self-harm (aHR, 0.56).

“Within the GLP [class], semaglutide comes out as a clear winner,” Taylor said.

Taylor emphasized that the observed benefits are likely multifactorial. While improved metabolic health may contribute, emerging evidence suggests potential direct central nervous system effects.

“There does appear to be a central effect to a brain effect, and we're not quite sure what the mechanism of that is,” he said.

Taylor said randomized controlled trials are needed to better understand the relationship between GLP-1s and psychiatric health, but they are expensive and difficult to organize. He said it would be helpful to compare Zepbound or Mounjaro to semaglutide or assess correlations on dose response.

“Is a higher dose of a GLP one going to be more effective or not? We don't know that yet,” Taylor said.

Taipale H, Taylor M, Markku Lähteenvuo, Ellenor Mittendorfer-Rutz, Antti Tanskanen, Jari Tiihonen. Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study. The Lancet Psychiatry. 2026;13(4):327-335. 

doi:https://doi.org/10.1016/S2215-0366(26)00014-3

Taylor, M. GLP-1s Linked to Reduced Anxiety, Suicidality, With Mark Taylor, MD. HCPLive. Published March 21, 2026. Accessed March 24, 2026. 

https://www.hcplive.com/view/glp-1-receptor-agonists-linked-reduced-anxiety-suicidality-mark-taylor-md

Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. US Food & Drug Administration. Published January 13, 2026. Accessed March 20, 2026. 

https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type

Videos

National cohort study finds semaglutide tied to reduced depression, anxiety, and self-harm risk in patients with diabetes and comorbid mental illness.
 

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Therapeutic innovation in gastroenterology has accelerated over the past decade, reshaping how clinicians evaluate treatment response, define success, and identify unmet needs across inflammatory and metabolic diseases. As the armamentarium expands, so too does the complexity of decision-making in both inflammatory bowel disease (IBD) and broader digestive disorders. The question is no longer whether options exist, but how to deploy them effectively—and when to pivot.

Advancing Gastroenterology from the Frontlines of Patient Care

, a gastroenterologist specializing in inflammatory bowel diseases at 

, explains that early identification of suboptimal response remains grounded in careful clinical reassessment. In the absence of predictive biomarkers that reliably match individual patients to specific agents, clinicians must synthesize disease severity, distribution, comorbidities, and patient preferences. Clinical trial data provide practical benchmarks—particularly regarding expected timelines for response. Some therapies demonstrate benefit within weeks, whereas others may require months, informing when optimization or switching should be considered.

, noted that 2025 marked a banner year for guideline development across ulcerative colitis, metabolic liver disease, and gastrointestinal bleeding. Institutional leadership in translational research continues to bridge laboratory discovery and bedside application, reinforcing the importance of evidence-based adaptation as new mechanisms of action emerge.

McDonald anticipates that emerging therapies—including anti-fibrotic strategies in Crohn disease—may necessitate new monitoring paradigms. While core goals remain unchanged—symptom control, mucosal healing, and durable remission—success metrics may expand as clinicians begin treating disease phenotypes previously managed surgically.

Cohen highlighted additional clinical lessons from 2025, including the growing use of combination biologic strategies to overcome therapeutic ceilings and the expanding investigation of glucagon-like peptide-1–based agents beyond metabolic indications. Looking ahead, both physicians identified precision medicine and microbiome-directed interventions as critical areas for trial development. Cohen emphasized prevention as a particularly underexplored frontier, including efforts to identify microbiome alterations preceding overt disease.

Together, their perspectives underscore a shared priority: refining therapeutic sequencing, improving patient-specific targeting, and designing clinical trials that better anticipate real-world complexity while advancing measurable, durable outcomes in digestive disease care.

Discover how new IBD therapies, combo drugs, and microbiome research aim to predict response, prevent Crohn’s complications, and expand trial options.

Advancing Gastroenterology from the Frontlines of Patient Care 

Allergist-immunologist at Yale New Haven Hospital

Why De-Labeling NNAALs Should Be Routine Obstetrics Care, With Chang Su, MD

With maternal non-narcotic analgesic allergy labels significantly associated with eclampsia (aRR, 1.5; 95% CI, 1.06–2.12), preterm birth (aRR, 1.21; 95% CI, 1.14–1.28), NICU admission (aRR, 1.17; 95% CI, 1.10–1.25), and neonatal withdrawal syndrome (aRR, 1.51; 95% CI, 1.24–1.84) across a California birth cohort of 2,244,210 singleton livebirths, the case for integrating allergy de-labeling into routine obstetric care is compelling.

American Academy of Allergy, Asthma & Immunology (AAAAI)

 2026 Annual Meeting held in Philadelphia, Pennsylvania, from February 27 to March 2, with Chang Su, MD, allergist-immunologist at Yale New Haven Hospital, who conducted the research during her time at University of California San Francisco, she situated the NNAAL findings within a broader de-labeling effort already underway in obstetrics. Her group has had significant success with beta-lactam allergy de-labeling in collaboration with OB and primary care colleagues — driven in part by prior data showing that penicillin allergy labels, like NNAALs, divert patients away from first-line therapy, in that case for Group B streptococcal infection around the time of delivery. Approximately 90% of patients with a beta-lactam allergy label do not have a true allergy on formal evaluation, with emerging data suggesting the true negative rate may be even higher. A similar dynamic appears to apply to NNAALs: one prior study found that approximately 85% of patients carrying such a label can ultimately tolerate NSAIDs, suggesting a substantial proportion of the 10,460 NNAAL-carrying mothers in the SABLE cohort may have been unnecessarily restricted from first-line analgesics and aspirin-based preeclampsia prevention.

Critically, Su emphasized that de-labeling is not an all-or-nothing proposition. For patients who cannot be fully cleared — due to the nature of their prior reaction — a formal allergy evaluation can still produce a concrete, individualized action plan specifying dose thresholds and tolerable agents. In the context of preeclampsia prevention, for example, a patient who cannot tolerate the recommended 162 mg aspirin dose may still safely receive 81 mg, a clinically meaningful alternative that would otherwise go unprescribed without specialist input. Su described ongoing efforts to expand this model beyond beta-lactams to other drug classes — including NNAALs — and stressed that the referral pipeline from OB-GYN colleagues is central to making de-labeling scalable as a component of routine prenatal care.

“For example, for preeclampsia prevention, aspirin 162 milligrams is often recommended. But for certain patients, perhaps they can tolerate 81 milligrams based on the types of reaction that they had. And if we can prove that, then perhaps we can't get them the most recommended therapy, but we can get the second best of them,” Su said.

Su has no relevant disclosures to report.

1. Su C, Baer R, Otani I, Schatz M, Chambers C. The relationship between maternal non-narcotic analgesics allergy labels and maternal and fetal outcomes: results from a large, administrative cohort. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Abstract #L24

2. Non-Narcotic Analgesics Allergy Labels Linked to Adverse Maternal and Fetal Outcomes. News release. AAAAI. February 26, 2026. 

https://www.aaaai.org/about/news/news/2026/narcotic

Su discussed the role of delabeling non-narcotic analgesic allergy labels in obstetrics care.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Mercedes Martinez, MD, is a professor of pediatrics and medicine, medical director of the intestinal transplant program at the Center for Liver Disease and Abdominal Organ Transplantation, and medical director of the pediatric abdominal organ transplantation program at NewYork-Presbyterian.

Expanding Maralixibat for Rare Cholestatic Liver Diseases: Cholestatic Pruritus Explained

For patients with rare cholestatic liver diseases, pruritus is a debilitating, often underrecognized symptom that can severely disrupt sleep, daily function, and quality of life. Frequently worsening at night and with heat or activity, it remains difficult to measure and does not reliably correlate with standard biomarkers like bile acids or bilirubin. As awareness grows and new therapies are being studied, there is increasing urgency to better recognize and more effectively treat this overlooked but life-altering burden.

, Mercedes Martinez, MD, a professor of pediatrics and medicine at CUMC, highlighted both the clinical burden of cholestatic pruritus and the growing promise of targeted therapies like maralixibat.

One of the central challenges, Martinez explained, is the lack of objective tools to quantify pruritus severity. Unlike laboratory markers such as bilirubin or bile acid levels, itch does not reliably correlate with measurable disease parameters. Some patients with markedly elevated bile acids report little to no pruritus, while others with only moderate elevations experience debilitating symptoms, a disconnect that can lead clinicians to underestimate the true burden of disease.

“That right there is a problem. We don't have an objective assessment of how much pruritus somebody can feel. It's a feeling, and because it's a feeling, sometimes people try to downplay it, and physicians don't recognize that this is a problem,” she explained. “Sometimes, when we don't understand something and we don't have an objective assessment or something, we try to downplay that.”

The consequences for patients, particularly children, can be profound. Martinez described cases of severe, relentless itching that disrupt sleep, limit physical activity, and significantly impair quality of life. In extreme instances, patients scratch to the point of bleeding or engage in harmful behaviors in an attempt to relieve symptoms. Pruritus is often worse at night, exacerbated by heat or physical exertion, and may go underreported because patients normalize the sensation over time. As a result, more proactive and specific questioning by clinicians is essential to fully capture symptom burden.

From a mechanistic standpoint, she says the role of bile acids is central. The body typically recycles approximately 95% of bile acids through reabsorption in the terminal ileum. In cholestatic disease, impaired bile acid handling contributes to symptom development.

Therapies that interrupt this recycling process can therefore help reduce pruritus. While older treatments such as bile acid sequestrants are poorly tolerated, newer ileal bile acid transporter (IBAT) inhibitors like maralixibat offer a more targeted approach by blocking bile acid reuptake and lowering systemic levels.

While it is already approved for conditions such as Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), where pruritus is a hallmark feature, Martinez noted that the underlying mechanism of cholestatic pruritus is shared across multiple liver diseases, suggesting broader therapeutic potential. In clinical practice, off-label use has shown benefit in conditions such as primary sclerosing cholangitis and biliary atresia, though access remains limited due to lack of formal approval.

She noted that this is where the ongoing EXPAND trial becomes critical. By evaluating maralixibat in a wider population of rare cholestatic liver diseases, the study aims to establish both efficacy and safety beyond its current indications. According to Martinez, expanding approval could alleviate not only the clinical burden of pruritus but also the financial and access barriers faced by families.

Ultimately, improving recognition of pruritus and broadening access to effective therapies may significantly transform care for patients living with these challenging conditions.

Editors’ Note: Martinez reports no relevant disclosures.

Brooks A. FDA Approves Maralixibat (Livmarli) Tablet for Alagille Syndrome, PFIC. HCPLive. April 14, 2025. Accessed March 24, 2026. 

https://www.hcplive.com/view/fda-approves-maralixibat-livmarli-tablet-alagille-syndrome-pfic

Mirum Pharmaceuticals. Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases. March 16, 2026. Accessed March 24, 2026. 

https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Completes-Enrollment-in-Phase-3-EXPAND-Study-of-LIVMARLI-maralixibat-in-Additional-Rare-Cholestatic-Liver-Diseases/default.aspx

Martinez discusses unmet needs in pruritus management and maralixibat’s potential to expand treatment of itch across rare cholestatic liver diseases.

Hepatology

Expanding the Reach of Maralixibat in Rare Cholestatic Liver Diseases, With Mercedes Martinez, MD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Recently, the American College of Gastroenterology (ACG) issued 24 new clinical recommendations for diagnosing, managing, and preventing hepatic encephalopathy (HE).

For diagnosis, the guidelines recommend against using ammonia alone to diagnose MHE/CHE or guide treatment decisions, against ordering routine brain imaging in cirrhosis patients with confusion unless there are new focal neurologic deficits, and advise always screening for mimics, including sleep apnea, alcohol-related conditions, and mild cognitive impairment.

For treatment, lactulose remains first-line, titrated to 2–3 soft bowel movements daily using the Bristol Stool Scale. PEG (4L) is a reasonable alternative to lactulose in acute OHE. Rifaximin should be added to lactulose in acute OHE, don't wait for lactulose to fail, and should be started 14 days before elective TIPS and continued for at least 6 months.

For nutrition, the guidelines recommend against protein restriction, noting it worsens outcomes, and target 1.2–1.5 g/kg/day protein, or up to 2 g/kg/day in critically ill patients. A late-night snack is recommended, as is BCAA supplementation if protein needs cannot be met through diet alone. Exercise is beneficial despite transient ammonia rises.

For discharge and follow-up, medication reconciliation at discharge is essential, with a review of opiates, benzodiazepines, gabapentin, PPIs, and sleep aids. All patients should receive written and oral advice against driving within 3 months of an OHE episode, and caregivers should be screened for burnout.

For transplant, living donor transplant should be considered for patients with multiple HE episodes even if MELD is below 15, and adding 4–5 MELD points more accurately reflects true 90-day mortality risk in these patients.

These guidelines experts utilized the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) process to evaluate evidence quality, additionally highlighting additional key concept statements.

HCPLive spoke with an expert who helped formulate the guidelines, Jasmohan Bajaj, MD, MS, Professor of Medicine, Division of Gastroenterology, Hepatology, and Nutrition at Virginia Commonwealth University and Richmond VA Medical Center in Richmond, VA.

: This is the first major ACG update on hepatic encephalopathy in a couple of years. From your perspective, what are the most practice-changing updates clinicians should be aware of right away?

: Thank you for shining a spotlight on hepatic encephalopathy, and we are so happy that the college was also able to commission this guideline. The most practice-changing updates are: The first is that minimal or covert hepatic encephalopathy is an entire pre-clinical stage that is often not only ignored but confused for actual hepatic encephalopathy — we are missing things such as dementia, alcohol effects, or obstructive sleep apnea, and falsely diagnosing overt hepatic encephalopathy. Comorbid conditions are important. Ammonia has been given a lot of importance as the sole diagnostic and prognostic marker, and we need to get away from that. Ammonia should be one of many things, if at all, that informs our decision on whether someone has hepatic encephalopathy and how well or badly they're doing. Inpatient management of hepatic encephalopathy is critical, we want to make sure patients do not develop aspiration pneumonia, that they get treated very quickly, and that they are not discharged too soon before they and their family members are able to understand what actually happened and what the risks of recurrence are. We also added a concept called social infrastructure, because hepatic encephalopathy is not only a disease of the patient, it's a disease of the entire family and their ecosystem. A lot of these patients are not being counseled appropriately or to the extent that we are comfortable they understand the need for medications, medication affordability, and other details that require a deep social insight into what the patient and their family members are feeling. Prevention of recurrence is also important, ensuring patients have good contacts through apps, and making sure patients are not overdosed on lactulose. We often have blanket ways of prescribing lactulose, which frequently has very adverse GI side effects, causing some people to stop taking it prematurely. We have recommended use of the Bristol Stool Scale, which tells you the quality of stool and not just the quantity, giving control back to patients and their caregivers to judge how much lactulose they actually need to take. Initiating rifaximin for secondary prophylaxis has not changed but remains important. And last but not least, ensuring these patients are connected to someone who can consider them for a liver transplant, particularly patients with recurrent hepatic encephalopathy episodes but a low MELD score, for whom living donor transplant should be considered.

: Despite these updated recommendations, where do you see the biggest unmet needs in HE, whether in diagnostics, therapeutics, or care delivery, and what should clinici ans watch for next?

 The important unmet needs are the underdiagnosis of covert or minimal hepatic encephalopathy, because those patients are still suffering, and we need to ensure we have the ability to exclude other comorbid conditions that our patients are unfortunately already prone to. The other unmet need is ensuring that patients are discharged properly — that the discharge handoff after an inpatient hepatic encephalopathy episode is done to the point where we are comfortable that the patients, their family members, and everyone involved understands what happened. This is very unique to each medical system, so one size does not fit all. And last but not least, ensuring that these patients get a fair shake when it comes to liver transplant — because with every hepatic encephalopathy episode, the brain develops further injury. Time is brain in hepatic encephalopathy as well, and we have to come up with ways to diagnose hepatic encephalopathy that can satisfy transplant boards to give patients extra points or consideration for a living donor transplant.

Are there any other aspects of the guidelines you'd like to highlight — perhaps around nutrition or the role of ammonia testing — that clinicians may still be getting wrong in practice?"

 I'd like to speak to both ammonia and protein. On nutrition, patients with cirrhosis are usually protein deficient, and even though they might be obese, they could be sarcopenic, meaning they have less functional muscle available to help improve systemic inflammation and clear ammonia from circulation. We want to use a combination of careful nutrition and exercise to ensure sarcopenia is addressed, and that means absolutely no protein restriction. The proteins with the least ammoniagenesis are typically vegetarian and dairy proteins compared to red meat, but you have to see what the patient actually eats, and that's where knowledge of social infrastructure comes in. What the patient can afford is also important. Another important point for the prevention of sarcopenia is a late-night snack — a mixture of carbohydrates and protein that prevents muscle loss overnight, because patients with cirrhosis have problems with gluconeogenesis during fasting. On ammonia, while ammonia is central to the pathogenesis of hepatic encephalopathy, where things get lost in translation is figuring out whether ammonia levels drawn from venous or arterial blood accurately reflect the stage of confusion or hepatic encephalopathy the patient is in, and whether checking them repeatedly adds anything beyond what we already know clinically. Patients with cirrhosis need ammonia levels checked very infrequently, if at all, and those levels should be interpreted in the light of your clinical judgment. In other words, no one who is alert and oriented with cirrhosis should be treated just for a high ammonia level, you should be treating the patient, not their lab value.

Bajaj reports relevant disclosures with Bausch/Salix, Grifols, Cosmo, and others.

Bajaj JS, Jakab SS, Jesudian AB, et al. ACG Clinical Guideline: Hepatic Encephalopathy. 

https://doi.org/10.14309/ajg.0000000000003899

‌ACG Hepatic Encephalopathy Guideline Summary - Guideline Central. Guidelinecentral.com. Published 2026. Accessed March 24, 2026. 

https://www.guidelinecentral.com/guideline/5115195/#section-5115242

Articles

The updated ACG hepatic encephalopathy guidance reframes diagnosis around clinical assessment and exclusion of mimics, de-emphasizing ammonia and avoiding routine neuroimaging absent focal deficits. Treatment emphasizes rapid inpatient stabilization, lactulose titrated by stool quality, early rifaximin co-therapy, and peri-TIPS prophylaxis. Nutrition prioritizes preventing sarcopenia with adequate protein, late-night snacks, and selective BCAA use, supported by exercise. Discharge planning is positioned as a core intervention, including medication reconciliation, driving restrictions, caregiver support, and earlier transplant consideration despite low MELD.

ACG's 24 new HE recommendations tackle ammonia testing, lactulose titration, protein intake, and transplant criteria for cirrhosis patients.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

ACG Issues New Hepatic Encephalopathy Guidelines For Diagnosis, Treatment, Nutrition, and Transplant, With Jasmohan Bajaj, MD, MS

Xiao Xiao, PhD, from the Behavioral and Cognitive Neuroscience Center at Fudan University.

Study reveals chronic pain reshapes hippocampus, driving depression risk. Microglia may be a therapeutic target, says Xiao.

Pain

The HCPLive pain page is a resource for medical news and expert insights on pain medicine. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for acute pain, chronic pain, addiction medicine, and more.

Chronic Pain

On the HCPLive chronic pain page, resources on the topics of medical news and expert insight into pain treatment can be found. Content includes articles, interviews, videos, podcasts, and breaking news on chronic pain, and more.

Chronic Pain, Depression Linked Through Hippocampal Remodeling, With Xiao Xiao, PhD

Accelerated rTMS shows comparable efficacy to standard care, with delayed response in some patients and no clear predictors of early benefit.

Accelerated 5×5 rTMS Matches Standard Protocols in TRD, With Andrew Leuchter, MD

Podcasts

In this episode of the Skin of Color Savvy podcast, 2 leaders in dermatology discuss the complexities of colorism and its impact on pigmentary disorders.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Skin of Color Savvy: Tackling Colorism in Dermatology, With Seemal Desai, MD, and Pearl Grimes, MD

Akl Fahed, MD, MPH, Interventional Cardiologist at Massachusetts General Hospital and Instructor in Medicine at Harvard Medical School.

A metabolic polygenic risk score built from 20 traits and more than 8.5 million individuals outperformed existing disease-prediction models.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

When DNA Meets BMI: A New Way to Predict Metabolic Disease Earlier, With Akl Fahed, MD, MPH

Chris Bunick, MD, PhD, and Lindsay Ackerman, MD, preview the 2026 American Academy of Dermatology Annual Meeting.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

ABCs in Dermatology

Welcome to ABC’s in Dermatology, HCPLive’s newest dermatology podcast, hosted by a pair of the field’s leading minds in Lindsay Ackerman, MD, and Chris Bunick, MD, PhD.

Created by the same team behind The Medical Sisterhood and Skin of Color Savvy, ABCs in Dermatology is a monthly podcast designed to deliver candid conversations, clinical insight, and forward-looking perspectives from the voices shaping dermatology today.

ABCs in Dermatology: Previewing the 2026 AAD Annual Meeting

Hear Martha Gulati, MD, MS, reveal how mentorship and have shaped her career in women’s heart care.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Women's Health

On the HCPLive women's health page, resources on the topics of medical news and expert insight into obstetrics, gynecology, and women's related health can be found. Content includes articles, interviews, videos, podcasts, and breaking news on women's health, and more.

Moving the Needle in Medicine

Moving the Needle in Medicine is a monthly podcast from HCPLive Cardiology exploring the backstories and nuanced career paths that led the field’s movers and shakers to where they are today. Hosted by Alex Hajduczok, MD, the show will offer listeners insight into the biggest names in cardiology and beyond. 

This podcast is available via video on YouTube and on the HCPLive Cardiology podcast platforms on popular audio players.

Moving the Needle in Medicine: Blazing a Trail in Cardiology, with Martha Gulati, MD, MS

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

This release by Apogee Therapeutics highlights findings from the phase 2 APEX trial on zumilokibart (APG777) in adults with moderate to severe atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

APEX: Zumilokibart Shows Durable Response at 52 Weeks in Atopic Dermatitis

David Fleischer, MD, professor of pediatrics at Children’s Hospital Colorado.

In this Q&A, Fleischer discusses clinically meaningful gains in peanut allergy desensitization, strong response rates, and the path toward FDA submission for VP250.


Food Allergy

VIASKIN Peanut Patch Shows Strong Phase 3 VITESSE Results, With David Fleischer, MD

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Phase 3b ENCORE shows inhaled ARIKAYCE boosts culture conversion and symptoms in antibiotic‑naïve MAC lung disease, paving way for 2026 label expansion.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

ENCORE: ARIKAYCE Meets End Points, Improves Respiration in MAC Lung Disease

Pamela B. Morris, MD, is a professor of medicine in Cardiology and the Paul V. Palmer Chair of Cardiovascular Disease Preventionat the Medical University of South Carolina. 

New dyslipidemia guidance sharpens risk with CAC, checks lipoprotein(a), and targets LDL goals using expanded therapies for prevention.

Latest News

Semaglutide Linked to Lower Suicidality Risk in Diabetes, With Mark Taylor, MD

Advancing Gastroenterology from the Frontlines of Patient Care

Why De-Labeling NNAALs Should Be Routine Obstetrics Care, With Chang Su, MD

Expanding the Reach of Maralixibat in Rare Cholestatic Liver Diseases, With Mercedes Martinez, MD

ACG Issues New Hepatic Encephalopathy Guidelines For Diagnosis, Treatment, Nutrition, and Transplant, With Jasmohan Bajaj, MD, MS